We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




DNA Hypomethylation Predisposes to Type II Diabetes

By LabMedica International staff writers
Posted on 12 Jan 2012
A novel genomic screening technique that was used to compare DNA methylation variations between a group of individuals with type II diabetes and a group of normal individuals detected specific regions of hypomethylation in the DNA of the diabetes group.

Investigators at the Hebrew University of Jerusalem (Israel) designed a stepwise study to search for disease-contributing DNA methylation variations. More...
First, a pool based, genome-scale screen was carried out among 1169 type II diabetes cases and control individuals. Next, in-depth analyses were performed at selected top-ranking regions.

Results published in the January 15, 2012, online edition of the journal Human Molecular Genetics revealed an excess of differentially methylated sites in genomic regions that were previously associated with type II diabetes through genetic studies. A clear-cut region of hypomethylation was identified in the DNA of the type II diabetes cases relative to controls. The effect was independent of the sequence polymorphism in the region and persisted among individuals carrying the sequence-risk alleles. The odds of belonging to the type II diabetes group were increased by 6.1% for every 1% decrease in methylation.

A prospective study carried out in an independent population cohort revealed significant hypomethylation of young individuals that later progressed to type II diabetes, relative to the individuals who stayed healthy. Further genomic analysis revealed co-localization with gene enhancers and with binding sites for methylation-sensitive transcriptional regulators.

The data uncovered by this study showed that, “Low methylation levels at the analyzed sites were an early marker of type II diabetes and pointed to a novel mechanism by which early-onset, interindividual methylation variation at isolated nonpromoter genomic sites predisposes to type II diabetes.”

Related Links:

Hebrew University of Jerusalem




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automated Clinical Chemistry Analyzer
Envoy 500+
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.